Clinical trials: Pulmonary Hypertension (PH)
Pulmonary Hypertension, Cardiovascular Diseases
CVD/PH and Voice Characteristics
The purpose of this study is to determine the association between patient voice signal characteristics and the presence and severity of pulmonary hypertension in patients referred for elective clinically indicated…
- Trial name
- NCT07311044
- Where
- United States
- Volunteers
- 7,000 people
- Sponsor
- Mayo Clinic
Pulmonary Hypertension
Feasibility of Novel Clinical Trial Infrastructure, Design and Technology for Early Phase Studies in Patients With Pulmonary Hypertension (FIT-PH)
Prospective, open-label, observational study to evaluate the safety and feasibility of using pulmonary artery pressure (PAP) monitors and wearable activity monitors in patients with pulmonary hypertension (PH).
- Trial name
- FIT-PH (NCT04078243)
- Testing
- CardioMEMS HF System
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Hypertension, Pulmonary
Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension
Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic…
- Trial name
- e-MOTION PH (NCT02536534)
- Testing
- Correlation assessment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Bayer
Pulmonary Hypertension (Diagnosis), Pre-operative Assessment
GUARD-PH: Guided Use of AI-ECG for Risk Detection of PH in Surgery (GUARD-PH Trial)
This study is a prospective, open-label, randomized controlled trial designed to evaluate a new artificial intelligence (AI) tool for heart monitoring.
- Conditions
- Pulmonary Hypertension (Diagnosis), Pre-operative Assessment, Postoperative Complications (Cardiopulmonary), Treatment Outcomes
- Trial name
- GUARD-PH (NCT07344207)
- Testing
- Artificial Intelligence-Enabled Electrocardiography System
- Where
- Taiwan
- Volunteers
- 1,380 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Pulmonary Arterial Hypertension
An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension
This study is an international, multi-center, open-label study designed to provide oral treprostinil (UT-15C) to eligible subjects with pulmonary arterial hypertension who have completed the TDE-PH-310 study.
- Trial name
- NCT01560637
- Testing
- UT-15C (treprostinil diolamine)
- Where
- 153 sites in United States, Argentina and 21 more
- Volunteers
- 471 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension
PH-DyPred: A Multimodal Dynamic Risk Prediction Study in Pulmonary Hypertension
Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by elevated pulmonary artery pressure and vascular remodeling, which leads to right heart failure and increased mortality.
- Trial name
- PH-DyPred (NCT07131241)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Hypertension, Pulmonary
Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)
Researchers are looking for new ways to treat people with a type of pulmonary hypertension called combined postcapillary and precapillary pulmonary hypertension (Cpc-PH).
- Trial name
- HARMONIZE (NCT06814145)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Belgium and 10 more
- Volunteers
- 440 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Hypertension
Monitoring of the Influence of Approved PH-therapies RV-PA Coupling
The goal of this observational study is to learn about the acute (days) changes in right ventricular functions caused by initiation of pharmacological therapies in patients with precapillary pulmonary hypertension.
- Trial name
- NCT05935865
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University of Giessen
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Pulmonary Hypertension Associated With Sickle Cell Disease
Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)
This is a multicenter, randomized (2:1; oral treprostinil:placebo), double-blind, placebo-controlled event-driven (time to pulmonary hypertension [PH] clinical worsening) study in subjects with PH associated with sickle cell…
- Trial name
- NCT03055234
- Testing
- Oral Treprostinil
- Sponsor
- United Therapeutics
Pulmonary Hypertension
Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
This study will assess the impact of sacubitril/valsartan on elevated pulmonary artery (PA) pressures in patients with heart failure (HF) with preserved ejection fraction (HFpEF), measured using a previously implanted hemodynamic…
- Trial name
- ARNIMEMS-HFpEF (NCT04753112)
- Testing
- Sacubitril / Valsartan Oral Tablet [Entresto]
- Where
- Spain
- Volunteers
- 14 people
- Sponsor
- Germans Trias i Pujol Hospital
Hypertension, Pulmonary
A Study for the Identification of Biomarker Signatures for Early Detection of Pulmonary Hypertension (PH)
The primary purpose of this study is to identify and develop biomarker signatures based on circulating micro ribonucleic acid (RNA) in the blood samples associated with high risk of pulmonary hypertension (PH) to assist in the…
- Trial name
- CIPHER (NCT04193046)
- Testing
- Blood Sample
- Where
- 49 sites in United States, Belgium and 7 more
- Volunteers
- 907 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs.
- Conditions
- Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, Dyspnea
- Trial name
- BETTER COPD-PH (NCT05937854)
- Testing
- Tadalafil
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- VA Office of Research and Development
Interstitial Lung Disease, Pulmonary Hypertension
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis
This study aims to evaluate a noninvasive magnetic resonance imaging technique using hyperpolarized xenon gas to measure lung function in adults with interstitial lung disease, pulmonary hypertension, and systemic sclerosis.
- Conditions
- Interstitial Lung Disease, Pulmonary Hypertension, Systemic Sclerosis
- Trial name
- NCT07821398
- Testing
- Hyperpolarized 129 Xenon Gas
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Pulmonary Hypertension, Interstitial Lung Disease
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT07816185
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 3 sites in United States
- Volunteers
- 376 people
- Sponsor
- Pulmovant, Inc.